This study investigates genome-associated mechanisms of diabetic nephropathy and evaluates nephroprotective therapy in patients with type 2 diabetes mellitus in the Kazakh population. It examines markers such as glycation genes and beta 2 microglobulin, with the goal of developing more effective methods for early detection of diabetic nephropathy, a leading cause of chronic kidney disease. Enrollment is by invitation and open to consenting patients of Kazakh nationality, aged 18 to 65, with a verified diagnosis of type 2 diabetes.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * consent of the participant (signing the informed consent form); * patients with a verified diagnosis of type 2 diabetes mellitus of Kazakh nationality * age from 18 years to 65 years Exclusion Criteria: өage under 18 and over 65 years * undiagnosed type 2 diabetes mellitus * lack of informed consent * pregnancy and lactation at the time of inclusion in the study; * oncological disease at the time of inclusion in the study, decompensated concomitant somatic pathology.